2023
Appearance of tolerance-induction and non-inflammatory SARS-CoV-2 spike-specific IgG4 antibodies after COVID-19 booster vaccinations
Akhtar M, Islam M, Khaton F, Soltana U, Jafrin S, Rahman S, Tauheed I, Ahmed T, Khan I, Akter A, Khan Z, Islam M, Khanam F, Biswas P, Ahmmed F, Ahmed S, Rashid M, Hossain M, Alam A, Alamgir A, Rahman M, Ryan E, Harris J, LaRocque R, Flora M, Chowdhury F, Khan A, Banu S, Shirin T, Bhuiyan T, Qadri F. Appearance of tolerance-induction and non-inflammatory SARS-CoV-2 spike-specific IgG4 antibodies after COVID-19 booster vaccinations. Frontiers In Immunology 2023, 14: 1309997. PMID: 38173725, PMCID: PMC10763240, DOI: 10.3389/fimmu.2023.1309997.Peer-Reviewed Original ResearchConceptsFuture vaccination strategiesIgG responsesVaccination strategiesVaccine typesImmunological toleranceImmune responseMRNA dosesSpecific IgG antibody responseIgG subclass analysisRobust IgG responseChAdOx1 nCoV-19IgG antibody responsePrimary IgG responseSARS-CoV-2 variantsHumoral immune responseMRNA vaccine dosesCOVID-19 vaccinationNumber of dosesSARS-CoV-2 spike receptorBooster dosesBooster vaccinationIgG4 levelsIgG4 responsesMRNA vaccinationIgG levels473. Trends among hospitalized pregnant patients with laboratory-confirmed SARS-CoV-2 — COVID-NET, 14 U.S. States, January 2021–January 2023
Havers F, Whitaker M, Milucky J, Patton M, Chatwani B, Chai S, Armistead I, Meek J, Openo K, Weigel A, Ryan P, Nunez V, Bye E, Rudin D, Engesser K, Bushey S, Moran N, Sutton M, Talbot H, Olsen K, Taylor C. 473. Trends among hospitalized pregnant patients with laboratory-confirmed SARS-CoV-2 — COVID-NET, 14 U.S. States, January 2021–January 2023. Open Forum Infectious Diseases 2023, 10: ofad500.543. PMCID: PMC10679218, DOI: 10.1093/ofid/ofad500.543.Peer-Reviewed Original ResearchSARS-CoV-2 testPositive SARS-CoV-2 testCOVID-19-Associated Hospitalization Surveillance NetworkHospitalized pregnant patientsPregnant patientsRespiratory symptomsClinical outcomesBooster dosesCOVID-19 respiratory symptomsIntensive care unit admissionPositive SARS-CoV-2SARS-CoV-2 infectionPrimary vaccination seriesSymptomatic pregnant patientsCare unit admissionAdverse clinical outcomesSevere clinical outcomesCOVID-19 vaccinationCOVID-19 infectionSARS-CoV-2Unit admissionVaccination seriesAsymptomatic patientsChart abstractionMechanical ventilationInfluenza and Up-to-Date COVID-19 Vaccination Coverage Among Health Care Personnel — National Healthcare Safety Network, United States, 2022–23 Influenza Season
Bell J, Meng L, Barbre K, Haanschoten E, Reses H, Soe M, Edwards J, Massey J, Reddy G, Woods A, Stuckey M, Kuhar D, Bolden K, Dubendris H, Wong E, Rowe T, Lindley M, Kalayil E, Benin A. Influenza and Up-to-Date COVID-19 Vaccination Coverage Among Health Care Personnel — National Healthcare Safety Network, United States, 2022–23 Influenza Season. MMWR Morbidity And Mortality Weekly Report 2023, 72: 1237-1243. PMID: 37943704, PMCID: PMC10651318, DOI: 10.15585/mmwr.mm7245a5.Peer-Reviewed Original ResearchConceptsNational Healthcare Safety NetworkCOVID-19 vaccination coverageHealth care personnelAcute care hospitalsVaccination coverageCOVID-19 vaccinationCare hospitalNursing homesInfluenza seasonCDC's National Healthcare Safety NetworkVaccine-preventable respiratory diseaseInfluenza vaccination coverageAnnual influenza vaccineHealth care facilitiesEvidence-based strategiesVaccine doseImmunization PracticesInfluenza vaccineRecommended vaccinesPrimary seriesRespiratory diseaseCare personnelCare facilitiesSafety NetworkVaccinationExcess Death Rates for Republican and Democratic Registered Voters in Florida and Ohio During the COVID-19 Pandemic
Wallace J, Goldsmith-Pinkham P, Schwartz J. Excess Death Rates for Republican and Democratic Registered Voters in Florida and Ohio During the COVID-19 Pandemic. JAMA Internal Medicine 2023, 183: 916-923. PMID: 37486680, PMCID: PMC10366951, DOI: 10.1001/jamainternmed.2023.1154.Peer-Reviewed Original ResearchConceptsExcess death rateDeath rateCOVID-19 pandemicLow vaccination ratesCOVID-19 vaccinationCross-sectional studyAge 25 yearsCOVID-19 vaccineHigher COVID-19 death ratesCOVID-19 death ratesCross-sectional comparisonMedian ageAdjusted analysisVaccination ratesExcess mortalityVaccination attitudesMAIN OUTCOMEWeekly deathsMortality rateExcess deathsMortality recordsMortality dataStudy sampleDeathVaccineDeveloping and testing a COVID-19 vaccination acceptance intervention: A pragmatic trial comparing vaccine acceptance intervention vs usual care – Rationale, methods, and implementation
Pyne J, Seal K, Manuel J, DeRonne B, Oliver K, Bertenthal D, Esserman D, Purcell N, Petrakis B, Elwy A. Developing and testing a COVID-19 vaccination acceptance intervention: A pragmatic trial comparing vaccine acceptance intervention vs usual care – Rationale, methods, and implementation. Contemporary Clinical Trials 2023, 133: 107325. PMID: 37652356, DOI: 10.1016/j.cct.2023.107325.Peer-Reviewed Original ResearchVaccination ratesHealthcare providersAcceptance interventionsCOVID-19 vaccine acceptanceOne-year clusterImplementation-effectiveness trialVaccine information sourcesLow vaccination ratesCOVID-19 vaccinationVA healthcare systemHealthcare system approachCOVID-19 vaccinePublic health campaignsMotivational interviewing techniquesGOV IDENTIFIERUsual careVaccine discussionsFuture vaccinationPragmatic trialSevere illnessVaccine acceptanceSignificant disabilityImplementation facilitationVaccination decisionsHealth campaignsInfection with alternate frequencies of SARS-CoV-2 vaccine boosting for patients undergoing antineoplastic cancer treatments
Townsend J, Hassler H, Emu B, Dornburg A. Infection with alternate frequencies of SARS-CoV-2 vaccine boosting for patients undergoing antineoplastic cancer treatments. Journal Of The National Cancer Institute 2023, 115: 1626-1628. PMID: 37599438, PMCID: PMC10699797, DOI: 10.1093/jnci/djad158.Peer-Reviewed Original ResearchConceptsReinfection riskAntineoplastic therapyAntibody dataSARS-CoV-2 infectionSARS-CoV-2 vaccinesChemotherapy-immunotherapy combinationsPfizer-BioNTech BNT162b2COVID-19 vaccinationHigh infection riskFrequent boostingRituximab therapyBreakthrough infectionsVaccination scheduleAntibody levelsBooster scheduleVaccination frequencyImmune responseAdditional interventionsReduced riskHigh riskHormonal treatmentGeneral populationNecessitating assessmentPatientsInfection riskEvidence of leaky protection following COVID-19 vaccination and SARS-CoV-2 infection in an incarcerated population
Lind M, Dorion M, Houde A, Lansing M, Lapidus S, Thomas R, Yildirim I, Omer S, Schulz W, Andrews J, Hitchings M, Kennedy B, Richeson R, Cummings D, Ko A. Evidence of leaky protection following COVID-19 vaccination and SARS-CoV-2 infection in an incarcerated population. Nature Communications 2023, 14: 5055. PMID: 37598213, PMCID: PMC10439918, DOI: 10.1038/s41467-023-40750-8.Peer-Reviewed Original ResearchConceptsSARS-CoV-2 infectionPrior infectionHybrid immunityInfection riskCOVID-19 vaccinationNon-pharmaceutical interventionsInfected residentsVaccinationInfectionDocumented exposureDelta periodCell exposureIncarcerated populationsExposureImmunityRiskAssociationPotential benefitsCorrectional facilitiesCrowded settingsResidentsPeriodAnti–SARS-CoV-2 Pharmacotherapies Among Nonhospitalized US Veterans, January 2022 to January 2023
Yan L, Streja E, Li Y, Rajeevan N, Rowneki M, Berry K, Hynes D, Cunningham F, Huang G, Aslan M, Ioannou G, Bajema K. Anti–SARS-CoV-2 Pharmacotherapies Among Nonhospitalized US Veterans, January 2022 to January 2023. JAMA Network Open 2023, 6: e2331249. PMID: 37651140, PMCID: PMC10472184, DOI: 10.1001/jamanetworkopen.2023.31249.Peer-Reviewed Original ResearchConceptsCOVID-19 pharmacotherapyVeterans Health AdministrationVeterans Integrated Service NetworkSARS-CoV-2Higher Charlson Comorbidity Index scoresCharlson Comorbidity Index scoreNon-Hispanic veteransComorbidity Index scoreProportion of patientsSymptomatic COVID-19Multivariable logistic regressionCOVID-19 vaccinationCohort studyMedicare databaseVHA careUS veteransMAIN OUTCOMEMedical conditionsHispanic veteransPharmacotherapyHealth AdministrationIndex scoreCommunity careNonhospitalized personsWhite veteransOmicron variant infection in inflammatory rheumatological conditions – outcomes from a COVID-19 naive population in Aotearoa New Zealand
Brooks J, Montgomery A, Dalbeth N, Sapsford M, Kee R, Cooper A, Quincey V, Bhana S, Gore-Massy M, Hausmann J, Liew J, Machado P, Sufka P, Sirotich E, Robinson P, Wallace Z, Yazdany J, Grainger R. Omicron variant infection in inflammatory rheumatological conditions – outcomes from a COVID-19 naive population in Aotearoa New Zealand. The Lancet Regional Health - Western Pacific 2023, 38: 100843. PMID: 37520279, PMCID: PMC10372177, DOI: 10.1016/j.lanwpc.2023.100843.Peer-Reviewed Original ResearchInflammatory rheumatic diseasesSARS-CoV-2 infectionHospitalisation/deathOmicron variant infectionConnective tissue diseaseRheumatic diseasesVariant infectionCOVID-19SARS-CoV-2 Omicron variantSingle vaccine doseCOVID-19 hospitalisationMultivariable adjusted modelsCOVID-19 vaccination statusMultivariable logistic regressionCOVID-19 vaccinationHigh vaccination ratesRituximab useVaccine doseInflammatory arthritisVaccination statusClinical factorsTissue diseaseDisease characteristicsVaccination ratesRisk factorsImpact of vaccine platform and BCG vaccination on antibody responses to COVID-19 vaccination
Messina N, Sperotto M, Puga M, da Silva P, de Oliveira R, Moore C, Pittet L, Jamieson T, Dalcolmo M, dos Santos G, Jardim B, Lacerda M, Curtis N, Croda J. Impact of vaccine platform and BCG vaccination on antibody responses to COVID-19 vaccination. Frontiers In Immunology 2023, 14: 1172851. PMID: 37465688, PMCID: PMC10352084, DOI: 10.3389/fimmu.2023.1172851.Peer-Reviewed Original ResearchConceptsRecent BCG vaccinationBCG vaccinationAntibody responseVaccine platformAnti-spike IgG responseCOVID-19 vaccinationCOVID-19 vaccineCoronaVac vaccinationPrior vaccinationVaccine responsesIgG responsesSecond doseIgG antibodiesHealthcare workersVaccinationChAdOx1CoronaVacCOVID-19VaccineMultiple factorsResponsePlaceboDoseTrialsAntibodies1184-P: No Increased Risk of Gestational Diabetes Mellitus (GDM) Diagnosis after COVID-19 Vaccination
VESCO K, DENOBLE A, LIPKIND H, KHARBANDA E, DESILVA M, DALEY M, GETAHUN D, ZERBO O, NALEWAY A, JACKSON L, WILLIAMS J, BOYCE T, FULLER C, VAZQUEZ BENITEZ G. 1184-P: No Increased Risk of Gestational Diabetes Mellitus (GDM) Diagnosis after COVID-19 Vaccination. Diabetes 2023, 72 DOI: 10.2337/db23-1184-p.Peer-Reviewed Original ResearchCOVID-19 vaccinationCOVID-19 vaccineRisk of GDMCOVID-19 vaccine dosesNon-Hispanic whitesGDM diagnosisVaccine dosesDisease controlGestational diabetes mellitus diagnosisDe novo diabetesRate of GDMDiagnosis of GDMVaccine Safety DatalinkPfizer Inc.Confidence intervalsICD-10 codesNon-Hispanic blacksDiabetes mellitus diagnosisOutcomes Research InstituteNon-Hispanic AsiansHealth care systemNonpregnant adultsUnvaccinated individualsIncreased riskRelative riskLongitudinal Assessment of Left Ventricular Function in Patients with Myopericarditis After mRNA COVID-19 Vaccination
NV B, McCollum S, Faherty E, Steele J, Karnik R. Longitudinal Assessment of Left Ventricular Function in Patients with Myopericarditis After mRNA COVID-19 Vaccination. Pediatric Cardiology 2023, 45: 1524-1532. PMID: 37294336, PMCID: PMC10251331, DOI: 10.1007/s00246-023-03200-2.Peer-Reviewed Original ResearchLeft ventricular longitudinal strainMRNA COVID-19 vaccinationCOVID-19 vaccinationSubclinical myocardial injuryEjection fractionFractional shorteningInitial presentationMyocardial injurySingle-center reviewMedian ejection fractionLeft ventricular functionVentricular longitudinal strainTime 0Area-length methodWilcoxon signed-rank testAcute illnessDiastolic functionVentricular functionDiastolic parametersLV functionRisk stratificationMyocardial recoveryTissue DopplerSigned-rank testMyopericarditisEnhanced IgG immune response to COVID‐19 vaccination in patients with sickle cell disease
Nakahara H, Cheedarla N, Verkerke H, Cheedarla S, Wu S, Hendrickson J, Chang A, McLemore M, Rassi F, Roback J, Neish A, Fasano R, Stowell S. Enhanced IgG immune response to COVID‐19 vaccination in patients with sickle cell disease. British Journal Of Haematology 2023, 202: 937-941. PMID: 37287128, PMCID: PMC10751105, DOI: 10.1111/bjh.18899.Peer-Reviewed Original ResearchConceptsSickle cell diseaseCOVID-19 vaccinationAntibody responseCell diseaseSARS-CoV-2 vaccinationIgG immune responseSimilar antibody responsesOptimal vaccination strategyIgG titresIgG responsesVaccination strategiesImmune responseSCD controlsGeneral populationPatientsVaccinationDiseaseResponseCohortTitresEffectiveness of COVID-19 Treatment With Nirmatrelvir–Ritonavir or Molnupiravir Among U.S. Veterans: Target Trial Emulation Studies With One-Month and Six-Month Outcomes
Bajema K, Berry K, Streja E, Rajeevan N, Li Y, Mutalik P, Yan L, Cunningham F, Hynes D, Rowneki M, Bohnert A, Boyko E, Iwashyna T, Maciejewski M, Osborne T, Viglianti E, Aslan M, Huang G, Ioannou G. Effectiveness of COVID-19 Treatment With Nirmatrelvir–Ritonavir or Molnupiravir Among U.S. Veterans: Target Trial Emulation Studies With One-Month and Six-Month Outcomes. Annals Of Internal Medicine 2023, 176: m22-3565. PMID: 37276589, PMCID: PMC10243488, DOI: 10.7326/m22-3565.Peer-Reviewed Original ResearchConceptsVeterans Health AdministrationCOVID-19 symptom onsetCOVID-19-related outcomesSevere COVID-19Six-month outcomesCOVID-19 vaccinationCOVID-19 treatmentCOVID-19SARS-CoV-2Percent of participantsUntreated control participantsCause mortalitySymptom onsetMedian ageOral antiviralsVHA careOutpatient treatmentHospitalizationHealth AdministrationDay 31U.S. veteransVariant transmissionMost veteransVeterans AffairsOne monthComparison of Female Ovarian Reserve Before vs After COVID-19 Vaccination
Yang L, Neal S, Lee T, Chou A, Schutt A, Gibbons W. Comparison of Female Ovarian Reserve Before vs After COVID-19 Vaccination. JAMA Network Open 2023, 6: e2318804. PMID: 37326996, PMCID: PMC10276301, DOI: 10.1001/jamanetworkopen.2023.18804.Peer-Reviewed Original ResearchCharacterizing healthcare worker attitudes toward the bivalent COVID-19 booster
Willebrand K, Fredrick J, Pischel L, Patel K, Roberts S, Murray T, Martinello R. Characterizing healthcare worker attitudes toward the bivalent COVID-19 booster. Antimicrobial Stewardship & Healthcare Epidemiology 2023, 3: s56-s57. PMCID: PMC10594485, DOI: 10.1017/ash.2023.300.Peer-Reviewed Original ResearchBooster doseBehavioral health unitHealthcare workersHealth unitsCOVID-19COVID-19 outbreakInpatient behavioral health unitFirst booster dosePrimary vaccination seriesCOVID-19 vaccinationCOVID-19 exposureBehavioral health settingsMonovalent vaccinationVaccination seriesBooster dosesBooster vaccineComplete responsePrevious vaccinationVaccine uptakeHealth HospitalGeneral populationSide effectsPsychiatric hospitalHealth settingsDemographic dataBiological rhythms in COVID-19 vaccine effectiveness in an observational cohort study of 1.5 million patients
Hazan G, Duek O, Alapi H, Mok H, Ganninger A, Ostendorf E, Gierasch C, Chodick G, Greenberg D, Haspel J. Biological rhythms in COVID-19 vaccine effectiveness in an observational cohort study of 1.5 million patients. Journal Of Clinical Investigation 2023, 133: e167339. PMID: 37053011, PMCID: PMC10231992, DOI: 10.1172/jci167339.Peer-Reviewed Original ResearchConceptsCOVID-19 vaccinationBreakthrough infectionsVaccine effectivenessVaccination timingCOVID-19 breakthrough infectionsCOVID-19-related hospitalizationCOVID-19 vaccine effectivenessBasic immune processesSecond booster doseObservational cohort studyEmergency department visitsMass vaccination programBooster doseVaccination timeBooster dosesCohort studyOlder patientsPatient ageDepartment visitsVaccine protectionCox regressionIsraeli cohortClinical endpointsVaccination programImmunization timeChallenges in Estimating the Effectiveness of COVID-19 Vaccination Using Observational Data
Hulme W, Williamson E, Horne E, Green A, McDonald H, Walker A, Curtis H, Morton C, MacKenna B, Croker R, Mehrkar A, Bacon S, Evans D, Inglesby P, Davy S, Bhaskaran K, Schultze A, Rentsch C, Tomlinson L, Douglas I, Evans S, Smeeth L, Palmer T, Goldacre B, Hernán M, Sterne J. Challenges in Estimating the Effectiveness of COVID-19 Vaccination Using Observational Data. Annals Of Internal Medicine 2023, 176: m21-4269. PMID: 37126810, PMCID: PMC10152408, DOI: 10.7326/m21-4269.Peer-Reviewed Original ResearchConceptsCOVID-19 vaccineRandomized trialsObservational studyCOVID-19 vaccinationDuration of protectionBooster vaccinationFirst doseTrial emulationNew virus variantsVaccinated personsEligible personsVaccine rolloutVaccinationTarget trialsVirus variantsTrialsVaccineTime-varying variablesBaselineRobust evidenceSingle trial approachRapid uptakePersonsConfoundersDoseRevaccination of patients with systemic lupus erythematosus or rheumatoid arthritis without an initial COVID-19 vaccine response elicits seroconversion in half of the patients.
Ammitzbøll C, Thomsen M, Andersen J, Jensen J, Bayarri-Olmos R, Garred P, Hermansen M, Johannsen A, Larsen M, Mistegaard C, Mikkelsen S, Nielsen L, Olesen R, Pérez-Alós L, Vils S, Szabados F, Søgaard O, Tolstrup M, Erikstrup C, Hauge E, Troldborg A. Revaccination of patients with systemic lupus erythematosus or rheumatoid arthritis without an initial COVID-19 vaccine response elicits seroconversion in half of the patients. Clinical And Experimental Rheumatology 2023, 42: 157-165. PMID: 37877429, DOI: 10.55563/clinexprheumatol/orpp04.Peer-Reviewed Original ResearchT cell responsesDetectable antibody responseBlood donorsSARS-CoV-2Antibody responseB cellsRheumatic diseasesCOVID-19 vaccine responsesSARS-CoV-2 antibodiesCOVID-19 mRNA vaccinesRevaccination of patientsSystemic lupus erythematosusB cell levelsCOVID-19 vaccinationPercent of casesDetectable serological responsesSARS-CoV-2 spike proteinAntibody class switchRD cohortLupus erythematosusVaccine responsesAntibody levelsRheumatoid arthritisSpecific IgGMRNA vaccinesTwelve-Month Follow-up of the Immune Response After COVID-19 Vaccination in Patients with Genitourinary Cancers: A Prospective Cohort Analysis
Meza L, Zengin Z, Salgia S, Malhotra J, Karczewska E, Dorff T, Tripathi A, Ely J, Kelley E, Mead H, Hsu J, Dizman N, Salgia N, Chawla N, Chehrazi-Raffle A, Muddasani R, Govindarajan A, Rock A, Liu S, Salgia R, Trent J, Altin J, Pal S. Twelve-Month Follow-up of the Immune Response After COVID-19 Vaccination in Patients with Genitourinary Cancers: A Prospective Cohort Analysis. The Oncologist 2023, 28: e748-e755. PMID: 36971500, PMCID: PMC10485287, DOI: 10.1093/oncolo/oyad067.Peer-Reviewed Original ResearchConceptsCOVID-19 vaccinationGenitourinary cancersRenal cell carcinomaBooster doseCell carcinomaImmune responseBlood samplesSevere acute respiratory syndrome coronavirus 2Acute respiratory syndrome coronavirus 2T-cell receptor sequencingRespiratory syndrome coronavirus 2Baseline blood samplesMajority of patientsMinority of patientsProspective cohort analysisSyndrome coronavirus 2Twelve-month followAntibody titer analysisCOVID-19 vaccineSeroconversion ratesMedian ageUrothelial cancerCoronavirus 2Prostate cancerCohort analysis
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply